TY - JOUR
T1 - B-cell prolymphocytic leukemia
T2 - A specific subgroup of mantle cell lymphoma
AU - Van Der Velden, Vincent H J
AU - Hoogeveen, Patricia G.
AU - De Ridder, Dick
AU - Schindler-van Der Struijk, Magdalena
AU - Van Zelm, Menno C.
AU - Sanders, Mathijs
AU - Karsch, Dennis
AU - Beverloo, H. Berna
AU - Lam, King
AU - Orfao, Alberto
AU - Lugtenburg, Pieternella J.
AU - Böttcher, Sebastian
AU - Van Dongen, Jacques J M
AU - Langerak, Anton W.
AU - Kappers-Klunne, Mies
AU - Van Lom, Kirsten
PY - 2014/7/17
Y1 - 2014/7/17
N2 - B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell malignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). B-PLL cases with a t(11;14) were redefined as MCL in the World Health Organization 2008 classification. We evaluated 13 B-PLL patients [7 being t(11;14)-positive (B-PLL+) and 6 negative (B-PLL-)] and compared them with MCL and CLL patients. EuroFlow-based immunophenotyping showed significant overlap between B-PLL+ and B-PLL-, as well as between B-PLL and MCL, whereas CLL clustered separately. Immunogenotyping showed specific IGHV gene usage partly resembling MCL. Gene expression profiling showed no separation between B-PLL+ and B-PLL- but identified 3 subgroups. One B-PLL subgroup clustered close to CLL and another subgroup clustered with leukemic MCL; both were associated with prolonged survival. A third subgroup clustered close to nodal MCL and was associated with short survival. Gene expression profiles of both B-PLL+ and B-PLL- showed best resemblance with normal immunoglobulin M-only B-cells. Our data confirm that B-PLL+ is highly comparable to MCL, indicate that B-PLL- also may be considered as a specific subgroup of MCL, and suggest that B-PLL is part of a spectrum, ranging from CLL-like B-PLL, to leukemic MCL-like B-PLL, to nodal MCL-like B-PLL.
AB - B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell malignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). B-PLL cases with a t(11;14) were redefined as MCL in the World Health Organization 2008 classification. We evaluated 13 B-PLL patients [7 being t(11;14)-positive (B-PLL+) and 6 negative (B-PLL-)] and compared them with MCL and CLL patients. EuroFlow-based immunophenotyping showed significant overlap between B-PLL+ and B-PLL-, as well as between B-PLL and MCL, whereas CLL clustered separately. Immunogenotyping showed specific IGHV gene usage partly resembling MCL. Gene expression profiling showed no separation between B-PLL+ and B-PLL- but identified 3 subgroups. One B-PLL subgroup clustered close to CLL and another subgroup clustered with leukemic MCL; both were associated with prolonged survival. A third subgroup clustered close to nodal MCL and was associated with short survival. Gene expression profiles of both B-PLL+ and B-PLL- showed best resemblance with normal immunoglobulin M-only B-cells. Our data confirm that B-PLL+ is highly comparable to MCL, indicate that B-PLL- also may be considered as a specific subgroup of MCL, and suggest that B-PLL is part of a spectrum, ranging from CLL-like B-PLL, to leukemic MCL-like B-PLL, to nodal MCL-like B-PLL.
UR - http://www.scopus.com/inward/record.url?scp=84904497464&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-10-533869
DO - 10.1182/blood-2013-10-533869
M3 - Article
C2 - 24891323
AN - SCOPUS:84904497464
SN - 0006-4971
VL - 124
SP - 412
EP - 419
JO - Blood
JF - Blood
IS - 3
ER -